证券研究报告 | 2025年12月24日 ——医药生物行业2025年12月投资策略 推荐关注CXO板块 行业研究 · 行业投资策略 医药生物 投资评级：优于大市（维持评级） 证券分析师：陈曦炳 0755-81982939 chenxibing@guosen.com.cn S0980521120001 证券分析师：马千里 010-88005445 maqianli@guosen.com.cn S0980521070001 证券分析师：张超 0755-81982940 zhangchao4@guosen.com.cn S0980522080001 证券分析师：彭思宇 0755-81982723 pengsiyu@guosen.com.cn S0980521060003 证券分析师：陈益凌 021-60933167 chenyiling@guosen.com.cn S0980519010002 证券分析师：凌珑 021-60375401 linglong@guosen.com.cn S0980525070003 证券分析师：肖婧舒 0755-81982826 xiaojingshu@guosen.com.cn S0 ...

Market Overview - On November 20, the A-share market experienced fluctuations, with the ChiNext index falling over 1% after initially rising more than 1.5%. The Shanghai Composite Index closed down 0.4%, the Shenzhen Component Index down 0.76%, and the ChiNext Index down 1.12% [2][3] - The total trading volume in the Shanghai and Shenzhen markets was 1.71 trillion yuan, a decrease of 17.7 billion yuan compared to the previous trading day [2] Sector Performance - The market saw rapid rotation of hotspots, with over 3,800 stocks declining. Notably, the computing hardware concept was active, while the banking sector performed strongly against the trend. The photolithography adhesive concept continued its strong performance [2] - Sectors that weakened included beauty care, tourism and hotels, food, and retail, indicating a collective downturn in consumer-related sectors [2] External Market Influence - In the overnight U.S. market, all three major indices fell on November 20. The Dow Jones Industrial Average dropped by 386.51 points (0.84%) to close at 45,752.26 points, the S&P 500 fell by 103.40 points (1.56%) to 6,538.76 points, and the Nasdaq Composite decreased by 486.18 points (2.15%) to 22,078.05 points [4][5] - European markets, however, saw gains, with the FTSE 100 rising by 20.24 points (0.21%), the CAC 40 increasing by 27.30 points (0.34%), and the DAX up by 115.93 points (0.50%) [4][5] Industry Developments - The Ministry of Finance and the Ministry of Industry and Information Technology released a draft for public consultation regarding the "Government Procurement Demand Standards for New Energy Vehicles," which aims to standardize procurement conditions and ensure fair treatment of suppliers [5][6] - The Guangdong Provincial Government issued a plan for the "National Digital Economy Innovation Development Pilot Zone (2025-2027)," targeting a digital economy core industry value-added share of over 16% of GDP by 2027 [6] - The Chinese Chemical and Physical Power Industry Association is addressing the ongoing losses in the lithium iron phosphate industry by proposing a cost index for pricing, aiming to curb price undercutting and promote sustainable development [6] Automotive Industry Insights - The China Passenger Car Association reported that from January to October 2025, the production of new energy vehicles reached 12.672 million units, marking a year-on-year increase of 28.1% and a penetration rate of 46.4% [10] Semiconductor Industry Outlook - The China Semiconductor Industry Association projected that the chip design industry could reach a scale of one trillion yuan by 2030, with a compound annual growth rate of 19.6% from 2006 to 2025 [13]

Group 1: Company Developments - Xinda Biologics announced that its dual receptor agonist, Masitide, achieved primary and all key secondary endpoints in Phase III clinical trials for obesity in China, showing a significant weight reduction of 20.08% compared to placebo in subjects with a BMI ≥30 [1] - Xinda Biologics plans to submit a marketing application for Masitide 9mg for adult weight management to the National Medical Products Administration [1] - RoboSense has secured a three-year exclusive partnership with FAW Toyota for a new electric vehicle model, marking the first Chinese tech company to enter Toyota's lidar supply chain [6] Group 2: Market Trends - The U.S. stock market experienced significant declines, with the Dow Jones down 386.51 points (0.84%), S&P 500 down 103.4 points (1.56%), and Nasdaq down 486.18 points (2.15%) [2] - The U.S. non-farm payrolls added 119,000 jobs in September, exceeding expectations of 50,000, indicating a shift in economic data and Federal Reserve stance [2] - The domestic smartphone market in China saw a shipment of 27.93 million units in September 2025, a year-on-year increase of 10.1%, with 5G phones accounting for 86.3% of total shipments [4] Group 3: Financial Performance - Luxshare Precision Holdings expects a mid-term profit increase of approximately 40% to 50% for the six months ending September 30, 2025, driven by effective product differentiation and sales strategies [13] - Yidu International Holdings reported a net profit of approximately HKD 1.218 billion for the six months ending September 30, 2025, reflecting an increase of about 1155% year-on-year [14] - NetEase reported a third-quarter net profit of approximately RMB 8.616 billion (USD 1.2 billion), a year-on-year increase of 31.77% [15][16]

Core Viewpoint - The approval of the innovative drug "Weipena Peptide Injection" by the National Medical Products Administration marks a significant achievement for the company and highlights the robust development of the biopharmaceutical industry in Hangzhou [1][2]. Group 1: Company Achievements - The innovative drug "Weipena Peptide Injection" (brand name: Paidakang) has been approved for market launch, showcasing the company's research capabilities [1]. - This is the fifth innovative drug approved in Hangzhou this year, reflecting the city's growing strength in biopharmaceutical innovation [1]. Group 2: Industry Development - Hangzhou accounts for 75% of the province's innovative drug applications, with 262 new drug applications registered this year, representing 40.5% of the total in the province [2]. - The city has 133 pharmaceutical manufacturing companies and approximately 103 clinical trial and new drug application institutions, indicating a solid industrial foundation [2]. - In the first three quarters, 177 clinical trial projects were approved, making up 71.9% of the total in the province [2]. Group 3: Service and Support Systems - Hangzhou has established a comprehensive and efficient service system to support biopharmaceutical innovation, focusing on regulatory and service balance [3]. - The city has implemented a "three commitments" approach to ensure timely communication and support for innovative drug companies [3]. - The market regulatory department has introduced various innovative measures to alleviate financial pressures and streamline processes for enterprises [4]. Group 4: Future Prospects - The city plans to promote a service model tailored to market regulation, benefiting more innovative entities and fostering industrial clustering [4]. - There is a commitment to enhance the entire lifecycle management and service of innovative drugs while ensuring drug safety [4].

Core Viewpoint - The article discusses the approval of Pegbio's innovative drug, Weipenaide injection, for improving blood glucose control in adults with type 2 diabetes, highlighting its efficacy, safety, and convenience in administration [4][6]. Drug Approval and Details - The National Medical Products Administration (NMPA) approved 129 applications, including Weipenaide injection, on November 12, 2025 [5]. - Weipenaide is a first-class innovative drug developed by Pegbio, utilizing polyethylene glycol modification of GLP-1 peptides to enhance bioactivity while reducing dosage [4]. Clinical Efficacy - Clinical trials show that after 24 weeks of treatment, HbA1c levels decreased by 1.37%, significantly outperforming the placebo group, with a cumulative reduction of 1.39% at 52 weeks [4]. - The drug demonstrated a rapid onset of action, with HbA1c dropping by 0.82% by the fourth week of treatment [6]. Weight Management and Additional Benefits - In patients with a BMI greater than 32 kg/m², the average weight loss after 52 weeks was 4.77 kg [6]. - Weipenaide also positively impacted cardiovascular risk factors, including blood pressure and lipid levels [6]. Safety Profile - The incidence of confirmed hypoglycemia was 0% over 26 weeks, with gastrointestinal adverse events being relatively low: nausea (8%), vomiting (5.1%), abdominal distension (5.1%), and diarrhea (7.3%) [6].